Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion type Assertion NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_head.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion description "[Therefore, SHIP2 remains a significant therapeutic target for the treatment of both obesity and type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_provenance.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion evidence source_evidence_literature NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_provenance.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion SIO_000772 15964236 NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_provenance.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion wasDerivedFrom befree-20150227 NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_provenance.
- NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_assertion wasGeneratedBy ECO_0000203 NP513385.RAnUsJUR4qpw3OJbe-ckrLSF2eXyMFTlvM0UuSc_HuSlY130_provenance.